Form 4: Sight Sciences Director Receives RSU Grant
Statement of Changes in Beneficial Ownership
Director Staffan Encrantz was granted 28,261 restricted stock units as part of the Sight Sciences non-employee director compensation program.
Summary
- Director Staffan Encrantz received a grant of 28,261 restricted stock units (RSUs) on June 4, 2026.
- The grant value is approximately $130,000 based on the closing price on the grant date.
- The RSUs are scheduled to vest on the earlier of June 4, 2027, or the date of the 2027 annual meeting of stockholders.
- Following this transaction, the reporting person holds 1,420,183 shares directly, with additional indirect holdings through a trust and investment fund.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in nature.
Positives
- Director compensation alignment through equity-based incentives.
- Continued long-term commitment from a significant shareholder and director.
Negatives
- None identified.
Risks
- Vesting is contingent upon the reporting person's continued service as a director through the vesting date.
Future Outlook
The RSUs will vest in one year, subject to continued board service.
Industry Context
StockSavvy.ai notes that standard equity-based compensation for non-employee directors is a common practice in the medical device sector to ensure board alignment with shareholder interests.
Comparison to Industry Standards
- The grant follows standard corporate governance practices for public companies regarding director compensation.
- The use of RSUs for board members is consistent with peer medical technology companies.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Compensation | Grant of RSUs under the Non-Employee Director Compensation Program. | 06/04/2026 | Standard alignment of director interests with shareholders. |
Related Party Transactions
- Reporting person is a trustee of the 1997 Staffan Encrantz and Margareta Encrantz Revocable Trust.
- Reporting person is the Chairman, CEO, and sole director of the investment manager for Allegro Investment Fund, L.P.
Stakeholder Impact
- Minimal impact on shareholders as this is a standard compensation event.
Next Steps
- Vesting of RSUs on June 4, 2027, or the 2027 annual meeting date.
Key Dates
| Date | Description |
|---|---|
| 06/04/2026 | Date of RSU grant transaction. |
| 06/05/2026 | Date of filing. |
| 06/04/2027 | Scheduled vesting date for the RSU grant. |
Keywords
Sight Sciences, SGHT, Form 4, Insider Trading, Director Compensation, Equity Grant
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.